Miglustat (Zavesca) for Niemann-Pick Type C

Type: drug

Status: EMA Approved (EU), FDA Approved (orphan drug for NP-C)

Developer: Actelion Pharmaceuticals (now Janssen)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026